Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (93)

Search Parameters:
Keywords = Sinopharm

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
16 pages, 1434 KiB  
Article
Exploring Immune Responses to SARS-CoV-2: Insights from Sinopharm (BBIBP-CorV)-Vaccinated Individuals in a Group of Venezuelan Admixed Volunteers
by Alexis Hipólito García, Soriuska José Mayora, Christian Medina, Inírida Amada Belisario, Wendy Yaqueline Martínez, Francis Isamarg Crespo and Juan Bautista De Sanctis
Biomedicines 2025, 13(7), 1550; https://doi.org/10.3390/biomedicines13071550 - 25 Jun 2025
Viewed by 455
Abstract
Background: Vaccines are crucial for preventing infectious diseases, as both humoral and cellular immune responses play a vital role in combating viral infections. The cellular immune response is crucial against SARS-CoV-2, particularly with the emergence of new variants that evade antibody neutralization. [...] Read more.
Background: Vaccines are crucial for preventing infectious diseases, as both humoral and cellular immune responses play a vital role in combating viral infections. The cellular immune response is crucial against SARS-CoV-2, particularly with the emergence of new variants that evade antibody neutralization. This study focuses on the immune memory response in individuals who have been vaccinated with the Sinopharm BBIBP-CorV vaccine. Methods: A cross-sectional study evaluated lymphocyte subpopulations using flow cytometry in 52 vaccinated adults (30 females, 22 males) who had been exposed to SARS-CoV-2 or diagnosed with COVID-19. Conducted from February to June 2023 during the Omicron variant’s circulation, this study assessed antigens—CD154 in CD4+ T cells, CD107 and CD314 in CD8+ T cells, CD314 in NK cells, and CD86 in CD19 B cells—after stimulation with viral peptides and an inactivated virus. Granzyme B and IFN-γ were quantified using ELISA. Results: The memory response, regardless of gender, age, or Body Mass Index (BMI), was mild but significant upon exposure to a viral antigen or inactivated virus. An increase in the secretion of IFN-γ and granzyme B was also observed. Conclusions: It is suggested that the vaccine was able to generate a mild long-term memory against the SARS-CoV-2 virus in vaccinated adult individuals, independent of gender and BMI. Full article
Show Figures

Figure 1

22 pages, 4566 KiB  
Article
Immune Dysregulation at the Maternal–Fetal Interface Exacerbates Adverse Pregnancy Outcomes in an Inflammatory Arthritis Murine Model
by Chenxi Yang, Wenjuan Li, Xinxin Liu, Zijun Ma, Jun Chen, Quan Gong, Zachary Braunstein, Xiaoquan Rao, Yingying Wei and Jixin Zhong
Biomedicines 2025, 13(6), 1440; https://doi.org/10.3390/biomedicines13061440 - 11 Jun 2025
Viewed by 682
Abstract
Objective: Inflammatory arthritis (IA) has been linked to a number of adverse pregnancy outcomes (APOs), but the mechanisms linking IA-related immune dysregulation to compromised reproductive success remain poorly understood. This project will examine how IA affects pregnancy outcomes and alters the associated [...] Read more.
Objective: Inflammatory arthritis (IA) has been linked to a number of adverse pregnancy outcomes (APOs), but the mechanisms linking IA-related immune dysregulation to compromised reproductive success remain poorly understood. This project will examine how IA affects pregnancy outcomes and alters the associated immune microenvironment using SKG (ZAP70W163C) mice, a mouse model that suffers from arthritis resembling human IA. Methods: IA was induced in SKG mice on a C57BL/6J background via mannan exposure. Wild-type C57BL/6 mice served as controls. Pregnancy rates, conception time, embryo resorption rates, and immune parameters (cytokine levels and splenic/lymph node/placental immune cell subsets) were analyzed. Joint pathology was evaluated via histology (HE is staining) and anti-CCP antibody levels. Flow cytometry was used to analyze immune populations within the spleen along with the associated lymphatic nodes. Results: Synovial hyperplasia, elevated anti-CCP, and systemic inflammation were all observed in IA mice. Compared to controls, IA mice demonstrated a reduced mating success rate, prolonged conception time, decreased pregnancy rates, and increased embryo resorption. IA mice showed elevated Th1/Th17 cytokines-IFN-γ, TNF-α, and IL-17, and an expansion of pro-inflammatory immune cells, including NK cells, CD11b+ myeloid cells, neutrophils, M1 macrophages, and Tc1, in the spleen/lymph nodes. Placental immune dysregulation featured increased NKT, NK, and CD4+ cell infiltration. Conversely, anti-inflammatory subsets, such as M2 macrophages and dendritic cells, were reduced. Conclusions: IA increased APOs and skewed the immune microenvironment toward a pro-inflammatory state dominated by Th1/Th17/Tc1 responses and cytotoxic cell activation. These findings highlight immune dysregulation as a key driver of IA-associated pregnancy complications, providing mechanistic insights for therapeutic intervention. Full article
(This article belongs to the Special Issue Pathogenesis, Diagnostics, and Therapeutics for Rheumatic Diseases)
Show Figures

Figure 1

17 pages, 1524 KiB  
Article
Application of Transcriptome Analysis for the Exploration of the Mechanism of Methionine Promoting the Synthesis of Cephalosporin C in Acremonium chrysogenum by Employing a Chemically Defined Medium
by Yifan Li, Zhen Chen, Wei Hong, Tao Feng, Xiwei Tian and Ju Chu
Fermentation 2025, 11(6), 325; https://doi.org/10.3390/fermentation11060325 - 6 Jun 2025
Viewed by 552
Abstract
To better analyze the biosynthesis mechanism of cephalosporin C (CPC) in Acremonium chrysogenum, single-factor omission experiments and Plackett–Burman (PB) experimental design were employed to identify key components in the chemically defined medium. Response surface methodology (RSM) was then applied to optimize the [...] Read more.
To better analyze the biosynthesis mechanism of cephalosporin C (CPC) in Acremonium chrysogenum, single-factor omission experiments and Plackett–Burman (PB) experimental design were employed to identify key components in the chemically defined medium. Response surface methodology (RSM) was then applied to optimize the concentrations of critical factors, achieving a final CPC titer of 4.70 g/L, which reached 59.54% of the titer obtained with complex medium. Methionine was identified as the most significant amino acid influencing CPC production during medium optimization. On the basis of these findings, transcriptomic analysis was conducted to elucidate the regulatory role of methionine. The results revealed that methionine enhances CPC biosynthesis by upregulating cysteine metabolism-related genes and activating primary metabolic pathways to supply precursors and energy for secondary metabolism. Additionally, methionine promoted hyphal swelling and arthrospore formation, leading to the upregulated expression of genes in CPC biosynthetic gene clusters. By integrating medium optimization with transcriptomic analysis, we provided more reliable insights into the regulatory role of methionine in A. chrysogenum growth and CPC biosynthesis using a chemically defined medium, offering valuable guidance for fermentation process optimization and subsequent metabolic engineering strategies. Full article
Show Figures

Figure 1

16 pages, 950 KiB  
Article
Shoulder Injury Related to Vaccine Administration (SIRVA) Following COVID-19 Vaccination: Correlating MRI Findings with Patient Demographics
by Naser Obeidat, Ruba Khasawneh, Ahmad Alrawashdeh, Ali M. Abdel Kareem, Mohammad K. Al-na’asan, Mohammad Alkhatatba and Suhaib Bani Essa
Tomography 2025, 11(5), 53; https://doi.org/10.3390/tomography11050053 - 2 May 2025
Viewed by 1305
Abstract
Objectives: Shoulder injury related to vaccine administration (SIRVA), previously observed with influenza vaccines, has gained clinical significance with widespread COVID-19 vaccination. However, few studies correlate vaccine types and demographic factors with the MRI findings of SIRVA. This study aimed to evaluate MRI findings [...] Read more.
Objectives: Shoulder injury related to vaccine administration (SIRVA), previously observed with influenza vaccines, has gained clinical significance with widespread COVID-19 vaccination. However, few studies correlate vaccine types and demographic factors with the MRI findings of SIRVA. This study aimed to evaluate MRI findings of SIRVA following COVID-19 vaccination and assess associations with vaccine type and patient characteristics. Methods: A retrospective cohort study was conducted on 35 patients with new-onset shoulder complaints within six weeks of COVID-19 vaccination between May 2021 and May 2022. MRI findings suggestive of SIRVA were reviewed, including subacromial bursitis, rotator cuff tears, and adhesive capsulitis. Demographic data, vaccine type, clinical symptoms, and treatments were collected. Follow-up interviews (1–30 September 2024) assessed symptom persistence and vaccine hesitancy. Descriptive statistics and Chi-square tests were used to explore associations. Results: Of the 35 patients (mean age 53.6 ± 9.0 years; 54.3% female), subacromial bursitis was the most common MRI finding (89.5%), followed by tendonitis (47.4%) and adhesive capsulitis (36.8%). Tendonitis correlated with older age (p = 0.024) and AstraZeneca vaccination (p = 0.033). Subacromial bursitis was linked to female sex (p = 0.013) and higher BMI (p = 0.023). Adhesive capsulitis was associated with receiving the Sinopharm vaccine (p = 0.029). Persistent symptoms (22.9%) were more common in younger patients, women, and those with right-sided injections. Conclusions: SIRVA following COVID-19 vaccination showed different MRI patterns associated with female sex, higher BMI, and vaccine type. Awareness of these patterns may expedite recognition of COVID-19-associated SIRVA in routine practice. Full article
Show Figures

Figure 1

25 pages, 11367 KiB  
Article
An mRNA Vaccine for Herpes Zoster and Its Efficacy Evaluation in Naïve/Primed Murine Models
by Linglei Jiang, Wenshuo Zhou, Fei Liu, Wenhui Li, Yan Xu, Zhenwei Liang, Man Cao, Li Hou, Pengxuan Liu, Feifei Wu, Aijun Shen, Zhiyuan Zhang, Xiaodi Zhang, Haibo Zhao, Xinping Pan, Tengjie Wu, William Jia and Yuntao Zhang
Vaccines 2025, 13(3), 327; https://doi.org/10.3390/vaccines13030327 - 19 Mar 2025
Cited by 1 | Viewed by 1700
Abstract
Background/Objectives: An overwhelming burden to clinics, herpes zoster (HZ), or shingles, is a painful disease that occurs frequently among aged individuals with a varicella-zoster virus (VZV) infection history. The cause of shingles is the reactivation of dormant VZV in the dorsal root ganglia/cranial [...] Read more.
Background/Objectives: An overwhelming burden to clinics, herpes zoster (HZ), or shingles, is a painful disease that occurs frequently among aged individuals with a varicella-zoster virus (VZV) infection history. The cause of shingles is the reactivation of dormant VZV in the dorsal root ganglia/cranial nerves of the human body. Patients with HZ experience sharp, intense, electric shock-like pain, which makes their health-related quality of life (HRQoL) extremely low. Methods: Various mRNA constructs were designed based on intracellular organelle-targeting strategies and AI algorithm-guided high-throughput automation platform screening and were then synthesized by in vitro transcription and encapsulated with four-component lipid nanoparticles (LNPs). Immunogenicity was evaluated on a naïve mouse model, long-term mouse model, and VZV-primed mouse model. Safety was evaluated by a modified “nestlet shredding” method for potential adverse effects induced by vaccines. Comparison between muscular and intradermal administrations was conducted using different inoculated approaches as well. Results: The best vaccine candidate, CVG206, showed robust humoral and cellular immune responses, durable immune protection, and the fewest adverse effects. The CVG206 administered intradermally revealed at least threefold higher humoral and cellular immune responses compared to intramuscular vaccination. The manufactured and lyophilized patch of CVG206 demonstrated good thermal stability at 2–8 °C during 9 months of storage. Conclusions: The lyophilized mRNA vaccine CVG206 possesses remarkable immunogenicity, long-term protection, safety, and thermal stability, and its effectiveness could even be further improved by intradermal administration, revealing that CVG206 is a promising vaccine candidate for HZ in future clinical studies. Full article
Show Figures

Figure 1

18 pages, 3577 KiB  
Article
Utilizing Microbial Inoculants to Alleviate Continuous Cropping Obstacles: Insights into the Metabolites and Transcriptomic Responses of Pinellia ternata
by Xinyu Wang, Mohammad Murtaza Alami, Shuqi Gong, Qinglin Cheng, Chaoqun Chen, Xinghui Li, Shumei Zhong, Zhigang He, Dilin Chen, Shengqiu Feng, Shenghu Chen and Shaohua Shu
Metabolites 2025, 15(3), 189; https://doi.org/10.3390/metabo15030189 - 11 Mar 2025
Viewed by 813
Abstract
Pinellia ternata (Thunb.) Breit is a widely used medicinal herb in Traditional Chinese Medicine (TCM). Still, its sustainable cultivation is threatened by continuous cropping obstacles, which disrupt soil ecosystems, reduce yield, and degrade quality. Objectives: This study explores the potential of microbial inoculants [...] Read more.
Pinellia ternata (Thunb.) Breit is a widely used medicinal herb in Traditional Chinese Medicine (TCM). Still, its sustainable cultivation is threatened by continuous cropping obstacles, which disrupt soil ecosystems, reduce yield, and degrade quality. Objectives: This study explores the potential of microbial inoculants to mitigate these challenges through integrated metabolomic and transcriptomic analyses. Methods: Soil samples from fields with and without continuous cropping issues were used to compare the effects of microbial inoculants on the secondary metabolism and gene expression of P. ternata. Results and Discussion: Metabolomic profiling identified 20,969 metabolites, with significant changes in lipid-like molecules (22.2%), organic acids (9.1%), and phenylpropanoids (7.0%) under microbial treatment. Notable increases in phenylalanine and caffeic acid levels were observed in microbial-inoculated plants. Correspondingly, transcriptomic analysis revealed the upregulation of phenylalanine ammonia-lyase (PAL) and other stress-related genes, confirming the metabolic shifts. Clustering and machine learning analyses highlighted the critical roles of metabolites and genes in enhancing plant resilience. Microbial inoculants improved secondary metabolite production. Implications: These findings provide valuable insights into the mechanisms of microbial-plant interactions and establish a sustainable approach for cultivating P. ternata, addressing the challenges of continuous cropping while improving crop productivity and quality. Full article
(This article belongs to the Section Microbiology and Ecological Metabolomics)
Show Figures

Figure 1

24 pages, 9258 KiB  
Article
Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used
by Carl Hartmut Göbel, Axel Heinze, Katja Heinze-Kuhn, Sarah Karstedt, Mascha Morscheck, Lilian Tashiro, Anna Cirkel, Qutyaba Hamid, Rabih Halwani, Mohamad-Hani Temsah, Malte Ziemann, Siegfried Görg, Thomas Münte and Hartmut Göbel
Vaccines 2025, 13(2), 113; https://doi.org/10.3390/vaccines13020113 - 23 Jan 2025
Viewed by 1805
Abstract
Background/Objectives: In this ongoing, multicenter, global cohort observational study, phenotypes of headaches after COVID-19 vaccination were directly compared between different vaccines. Methods: Phenotypes of postvaccinal headache were recorded in 18,544 participants. The study was launched immediately after the start of the [...] Read more.
Background/Objectives: In this ongoing, multicenter, global cohort observational study, phenotypes of headaches after COVID-19 vaccination were directly compared between different vaccines. Methods: Phenotypes of postvaccinal headache were recorded in 18,544 participants. The study was launched immediately after the start of the global COVID-19 vaccination campaign on 12 January 2021 and continued until 1 August 2023. Specific aspects of headaches and related variables were collected via an online questionnaire. The clinical headache characteristics of patients vaccinated with the Comirnaty (BioNTech), Jcovden (Johnson & Johnson), Sputnik V (Gamelaya), Covilo (Sinopharm), Spikevax (Moderna), Vaxzevria (AstraZeneca), and Convidecia (CanSino Biologics) vaccines were investigated. Results: Across all vaccines, the median and mean latency of headache onset after vaccine administration were 12 h and 23.3 h, respectively. The median and mean headache duration were 12 h and 23.3 h, respectively. When the nonreplicating viral vector vaccine Sputnik V was used, headaches occurred the fastest, with a latency of 17 h. The latencies for the Vaxzevria and Convidecia nonreplicating viral vector vaccines were 14.9 h and 19.1 h, respectively. The Covilo inactivated whole-virus vaccine had a latency of 20.5 h. The latencies of the mRNA-based Comirnaty and Spikevax vaccines were 26.0 h and 22.02 h, respectively. Analysis of variance revealed no significant differences in the mean duration of postvaccinal headache for the vaccines tested. Compared with the Comirnaty, Covilo, and Vaxzevria vaccines, the Spikevax vaccine induced significantly greater headache intensities. Vaxzevria was associated with a significantly higher frequency of concomitant symptoms than the other vaccines. Conclusions: The phenotype of postvaccinal headache can vary significantly between vaccines. These results have clinical implications for differentiating between postvaccinal headache and other primary and secondary headaches. This knowledge is clinically relevant in differentiating life-threatening vaccination complications, such as thrombotic syndromes, which are also associated with headaches. Based on these results, new diagnostic criteria for postvaccinal headaches can be developed. Full article
Show Figures

Graphical abstract

61 pages, 3993 KiB  
Systematic Review
COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis
by Angel Justiz-Vaillant, Kimberly Roopnarine, Shaundell Solomon, Alyssa Phillips, Solange Sandy, Alyssa Subero, Sarah Seepersad, Nicholas Span, Phalmanie Ramnath, Akaasha Ramnarine, Bimala Ramdath, Chelsea Rampaul, Renissa Ramdial, Dana Phagoo, Thalia Ramdhanie, Vinaya Moonilal, Emily-Marie Poliah, Steffan Poonwassie, Karishta Punilal, Sarah Panchoo, Justice Parris, Steven Oudit, Trudy Muir, Johnson Nicholas-Joseph, Bijay Raj Pandit, Sanjeev Pakeerah, Vesham Sookoo, Patrice Richards, Tishia John, Darren Gopaul, Sachin Soodeen, Odette Arozarena-Barbosa, Arlene Williams, Chandrashehkar Unakal, Rodolfo Arozarena Fundora, Reinand Thompson and Patrick Eberechi Akpakaadd Show full author list remove Hide full author list
Microorganisms 2025, 13(1), 135; https://doi.org/10.3390/microorganisms13010135 - 10 Jan 2025
Viewed by 2421
Abstract
This systematic review evaluated the effectiveness and side effects of various COVID-19 vaccines, with a focus on Trinidad and Tobago. The Pfizer-BioNTech and Moderna vaccines demonstrated the highest efficacy, particularly against COVID-19 variants, while Janssen and Sinopharm were comparatively less effective. mRNA vaccines, [...] Read more.
This systematic review evaluated the effectiveness and side effects of various COVID-19 vaccines, with a focus on Trinidad and Tobago. The Pfizer-BioNTech and Moderna vaccines demonstrated the highest efficacy, particularly against COVID-19 variants, while Janssen and Sinopharm were comparatively less effective. mRNA vaccines, such as Pfizer-BioNTech and Oxford-AstraZeneca, were associated with more frequent and severe side effects, including soreness, fever, and cardiovascular issues. The review also identified significant gaps in the current scientific literature regarding COVID-19 vaccination issues in Trinidad and Tobago. These gaps highlight the need for comprehensive research to address vaccination challenges, including public health communication, equitable access, and local perceptions of vaccine safety. This analysis provides a foundation for developing targeted strategies to improve vaccine effectiveness in the region. Full article
(This article belongs to the Special Issue Editorial Board Members’ Collection Series: SARS-CoV-2 and COVID-19)
Show Figures

Figure 1

15 pages, 1366 KiB  
Article
Effect of Homologous and Heterologous Booster in COVID-19 Vaccination
by Marija Vukčević, Mateja Despot, Aleksandra Nikolić-Kokić, Duško Blagojević, Milan Nikolić, Ana Banko, Tanja Jovanović and Dragana Despot
Pharmaceuticals 2024, 17(12), 1734; https://doi.org/10.3390/ph17121734 - 22 Dec 2024
Viewed by 1439
Abstract
Background: COVID-19 became a global health crisis in early 2020, and the way out of the crisis was the rapid development of vaccines by Sinopharm, Pfizer, and Sputnik, among others, which played a crucial role in controlling the pandemic. Therefore, this study aims [...] Read more.
Background: COVID-19 became a global health crisis in early 2020, and the way out of the crisis was the rapid development of vaccines by Sinopharm, Pfizer, and Sputnik, among others, which played a crucial role in controlling the pandemic. Therefore, this study aims to investigate the long-term immune response by measuring the levels of anti-S1 IgG antibodies induced by homologous and heterologous vaccination regimens. Methods: We investigated the titer of the anti-S1 IgG antibody produced for the viral surface antigen 3, 6 months after the second dose, before the third dose, and 1, 3, and 6 months after the third dose. Results: Anti-S1 IgG antibody levels significantly increased three/six months after the second dose and following the booster in individuals without prior COVID-19 infection who received all three homologous vaccine doses. The group that initially responded poorly to Sinopharm showed a significant and sustained increase after receiving the Pfizer booster. Additionally, prior SARS-CoV-2 infection between primary and booster vaccination boosted anti-S1 antibody titers in all individuals, regardless of the vaccine used. The highest vaccine efficacy was observed during the primary vaccination period and declined over time, especially during the omicron-dominant period. Conclusions: The results suggest that while homologous and heterologous booster doses can significantly enhance anti-S1 IgG antibody levels, prior SARS-CoV-2 infection and the type of vaccine administered influence the duration and magnitude of the immune response. Full article
(This article belongs to the Section Pharmacology)
Show Figures

Figure 1

10 pages, 2710 KiB  
Article
Protective Efficacy of an Inactivated Recombinant Serotype 4 Fowl Adenovirus Against Duck Adenovirus 3 in Muscovy Duck
by Yun Lin, Wenjie Jiang, Lihua Ma, Jiayu Zhang, Ye Tang, Qiuqi Kan, Haifeng Xiong, Jiayan Wu, Jun Zhang, Yiwen Niu, Wei Zhang, Shengnan Wang, Weikang Wang, Quan Xie, Tuofan Li, Zhimin Wan, Wei Gao, Hongxia Shao, Aijian Qin and Jianqiang Ye
Vaccines 2024, 12(12), 1357; https://doi.org/10.3390/vaccines12121357 - 30 Nov 2024
Viewed by 1067
Abstract
Background: Duck adenovirus 3 (DAdV-3) is an emerging pathogen that has caused severe economic losses to the duck industry in China. Recently, the infection of ducks with serotype 4 fowl adenovirus (FAdV-4) has also been reported in China. Therefore, an efficient bivalent vaccine [...] Read more.
Background: Duck adenovirus 3 (DAdV-3) is an emerging pathogen that has caused severe economic losses to the duck industry in China. Recently, the infection of ducks with serotype 4 fowl adenovirus (FAdV-4) has also been reported in China. Therefore, an efficient bivalent vaccine to control the diseases caused by DAdV-3 and FAdV-4 is extremely urgent. In our previous study, a recombinant FAdV-4 expressing Fiber-2 of DAdV-3 was generated and designated as rFAdV-4-Fiber-2/DAdV-3. Methods: Here, the recombinant virus rFAdV-4-Fiber-2/DAdV-3 was inactivated to serve as a bivalent vaccine, and its immunogenicity and protective efficacy against DAdV-3 were evaluated in Muscovy ducks. Results: The subcutaneous injection of rFAdV-4-Fiber-2/DAdV-3 could efficiently induce antibodies against Fiber-2 of DAdV-3 and neutralize antibodies against FAdV-4. After challenges with DAdV-3, in comparison with the non-immunized ducks, the immunized ducks did not show any bodyweight loss, gross lesions, or histopathologic change. Moreover, viral loads in livers and kidneys from immunized ducks were undetectable, whereas those in non-immunized ducks with challenge were significantly high. Conclusions: All these data demonstrate that the inactivated recombinant virus rFAdV-4-Fiber-2/DAdV-3 has the potential to be an efficient vaccine candidate against both FAdV-4 and DAdV-3, although efficacy for FAdV-4 needs to be confirmed experimentally. Full article
(This article belongs to the Section Vaccine Design, Development, and Delivery)
Show Figures

Figure 1

14 pages, 728 KiB  
Article
The Real-World Effectiveness of Inactivated COVID-19 Vaccines in Zimbabwe During the Omicron Variant Dominance: A Test-Negative Case–Control Study
by Azure Tariro Makadzange, Patricia Gundidza, Kimberly Cheryl Chido Konono, Margaret Gurumani and Chiratidzo Ndhlovu
Vaccines 2024, 12(12), 1303; https://doi.org/10.3390/vaccines12121303 - 22 Nov 2024
Viewed by 1182
Abstract
Background/Objectives: The COVID-19 pandemic has significantly impacted global health, with varying vaccine effectiveness (VE) across different regions and vaccine platforms. In Africa, where vaccination rates are relatively low, inactivated vaccines like BBIP-CorV (Sinopharm) and Coronovac (Sinovac) have been widely used. This study evaluated [...] Read more.
Background/Objectives: The COVID-19 pandemic has significantly impacted global health, with varying vaccine effectiveness (VE) across different regions and vaccine platforms. In Africa, where vaccination rates are relatively low, inactivated vaccines like BBIP-CorV (Sinopharm) and Coronovac (Sinovac) have been widely used. This study evaluated the real-world effectiveness of licensed inactivated COVID-19 vaccines in Zimbabwe during a period dominated by Omicron variants. Methods: We conducted a prospective, test-negative, case–control study among symptomatic adults across six Zimbabwean provinces from November 2022 to October 2023. Participants were categorized based on vaccination status, and nasopharyngeal swabs were collected for SARS-CoV-2 PCR testing. Vaccine effectiveness was assessed using conditional logistic regression, adjusting for various covariates such as age, sex, and comorbidities. Results: Among 5175 participants, 701 tested positive for SARS-CoV-2 and 4474 tested negative. The overall adjusted VE against symptomatic COVID-19 was 31% (95% CI: 5.3–49.7%) among verified vaccinated individuals. Boosted individuals demonstrated a higher VE of 59.8% (95% CI: 40.3–72.9%). VE decreased significantly to 24% (95% CI: −4.1–44.8%) in individuals vaccinated over a year prior. Similar VE was observed for BBIP-CorV (36.8%, 95% CI: 11.4–54.9%) and Coronovac (38.1%, 95% CI: 16.3–54.2%). Conclusions: This study indicates modest protection from inactivated COVID-19 vaccines against symptomatic Omicron infection, with significant enhancement following booster doses. These findings highlight the need for continued vaccine evaluation, particularly in resource-limited settings, to inform public health strategies and optimize vaccination programs. Full article
Show Figures

Figure 1

14 pages, 840 KiB  
Article
Predictors of Hospitalization in Breakthrough COVID-19 among Fully Vaccinated Individuals with Immune-Mediated Rheumatic Diseases: Data from SAFER-Study
by Débora Cerqueira Calderaro, Valéria Valim, Gilda Aparecida Ferreira, Ketty Lysie Libardi Lira Machado, Priscila Dias Cardoso Ribeiro, Sandra Lúcia Euzébio Ribeiro, Natalia Sarzi Sartori, Rodrigo Poubel Vieira de Rezende, Ana Karla Guedes de Melo, Vitor Alves Cruz, Adah Sophia Rodrigues Vieira, Adriana Maria Kakehasi, Aline Teixeira de Landa, Ana Paula Neves Burian, Flávia Maria Matos Melo Campos Peixoto, Camila Maria Paiva França Telles, Rafaela Cavalheiro do Espírito Santo, Katia Lino Baptista, Yasmin Gurtler Pinheiro de Oliveira, Vanessa de Oliveira Magalhães, Raquel Lima de Lima, Erika Biegelmeyer, Pietra Zava Lorencini, Andréa Teixeira-Carvalho, Edgard Torres dos Reis-Neto, Emília Inoue Sato, Marcelo de Medeiros Pinheiro, Odirlei André Monticielo, Viviane Angelina de Souza, Ricardo Machado Xavier and Gecilmara Salviato Pileggiadd Show full author list remove Hide full author list
Vaccines 2024, 12(9), 1031; https://doi.org/10.3390/vaccines12091031 - 9 Sep 2024
Cited by 1 | Viewed by 2059
Abstract
Breakthrough COVID-19 (occurring in fully vaccinated people) has been described. Data on its characteristics among immune-mediated rheumatic disease (IMRD) patients are scarce. This study describes breakthrough COVID-19 occurring in IMRD patients participating in the SAFER-study, a Brazilian multicentric cohort evaluating the safety, effectiveness, [...] Read more.
Breakthrough COVID-19 (occurring in fully vaccinated people) has been described. Data on its characteristics among immune-mediated rheumatic disease (IMRD) patients are scarce. This study describes breakthrough COVID-19 occurring in IMRD patients participating in the SAFER-study, a Brazilian multicentric cohort evaluating the safety, effectiveness, and immunogenicity of SARS-CoV-2 vaccines in patients with autoimmune diseases. A descriptive analysis of the population and a binary logistic regression model were performed to evaluate the predictors of COVID-19-related hospitalization. A p-value < 0.05 was significant. The included 160 patients were predominantly females (83.1%), with a mean (SD) age of 40.23 (13.19) years. The patients received two (19%), three (70%), or four (11%) vaccine doses. The initial two-dose series was mainly with ChAdOx1 (Oxford/AstraZeneca) (58%) or BBIBP-CorV (Sinopharm-Beijing) (34%). The first booster (n = 150) was with BNT162b2 (BioNtech/Fosun Pharma/Pfizer) (63%) or ChAdOx1 (29%). The second booster (n = 112) was with BNT162b2 (40%) or ChAdOx1 (26%). The COVID-19 hospitalization rate was 17.5%. IMRD moderate/high activity (OR: 5.84; CI: 1.9–18.5; p = 0.002) and treatment with corticosteroids (OR: 2.94; CI: 1.02–8.49; p = 0.0043) were associated with higher odds of hospitalization, while increasing the number of vaccine doses was protective (OR: 0.37; CI: 0.15–0.9; p = 0.032). These findings, along with previous reassuring results about the safety of the COVID-19 vaccines, argue in favor of booster vaccination in IMRD patients. Full article
Show Figures

Figure 1

13 pages, 2458 KiB  
Article
The Impact of COVID-19 Vaccination Side-Effects on Work Attendance among Saudi Healthcare Workers
by Jawaher Alguraini, Mohamed T. S. Saleem, Nahed N. Mahrous, Abbas Shamsan, Fatima Zia Zaidi, Ohoud S. Alhumaidan and Yahya F. Jamous
Infect. Dis. Rep. 2024, 16(4), 770-782; https://doi.org/10.3390/idr16040059 - 19 Aug 2024
Viewed by 1883
Abstract
Objective: This cross-sectional-survey-based study aimed to investigate the severity of side-effects from Coronavirus disease (COVID-19) mRNA (Pfizer, Moderna), viral vector DNA (Oxford-AstraZeneca, J&J/Janssen), inactivated virus (Sinopharm, Sinovac), and other vaccines among healthcare workers (HCWs) in Saudi Arabia, focusing on their impact on work [...] Read more.
Objective: This cross-sectional-survey-based study aimed to investigate the severity of side-effects from Coronavirus disease (COVID-19) mRNA (Pfizer, Moderna), viral vector DNA (Oxford-AstraZeneca, J&J/Janssen), inactivated virus (Sinopharm, Sinovac), and other vaccines among healthcare workers (HCWs) in Saudi Arabia, focusing on their impact on work attendance. Methods: A total of 894 HCWs residing in Saudi Arabia participated in this study from March 2023 to May 2023. Participants completed an online questionnaire assessing demographic information, vaccination status, comorbidities, vaccine side-effects, and missed work information after vaccination. Descriptive statistics and chi-square tests were used for data analysis. Results: The majority of participants were female (83.7%) and aged 25–34 years (42.8%). Most participants were predominantly vaccinated with mRNA vaccines. Common side-effects included pain at the injection site, fatigue, fever, and chills. However, no significant association was found between vaccine type, side-effects, and work absenteeism. While demographic factors such as age and healthcare profession did not influence work absenteeism, variations were observed among different racial groups. Conclusion: COVID-19 vaccination among HCWs in Saudi Arabia is associated with common side-effects, but their impact on work attendance is not significant. Understanding these implications can inform strategies to support the healthcare workforce and mitigate the impact on patient care and staffing during the ongoing COVID-19 pandemic. Full article
Show Figures

Figure 1

12 pages, 272 KiB  
Article
Rates of Vaccination against COVID-19 in Psychiatric Outpatients
by Mina Cvjetkovic Bosnjak, Dusan Kuljancic, Ana-Marija Vejnovic, Darko Hinic, Vladimir Knezevic, Dragana Ratkovic, Vanja Bosic, Vesna Vasic, Branislav Sakic, Darja Segan, Predrag Savic, Minja Abazovic, Masa Comic, Djendji Siladji, Dusica Simic-Panic and Olga Ivetic Poledica
J. Pers. Med. 2024, 14(7), 748; https://doi.org/10.3390/jpm14070748 - 14 Jul 2024
Cited by 1 | Viewed by 1657
Abstract
Background: The aim of this study was to compare the rates of vaccination against COVID-19 infection in psychiatric outpatients and the general population, as well as rates of infected patients. In addition, the level and type of anxiety due to the pandemic were [...] Read more.
Background: The aim of this study was to compare the rates of vaccination against COVID-19 infection in psychiatric outpatients and the general population, as well as rates of infected patients. In addition, the level and type of anxiety due to the pandemic were observed in patients with psychotic, anxiety, and depressive disorders. Materials and Methods: In the present study, 171 patients with pre-existing mental disorders completed the questionnaire about the doses and types of vaccination against COVID-19. During 2021–2023, patients with different mental disorders, aged from 18 to 80, were included. All patients filled in a self-reported questionnaire including general information (age, sex, marriage, education, working status, comorbid conditions) as well as questions about mental health, receiving vaccination, and the course of COVID-19 infection if it was present. All patients gave informed consent for the interview. Results: Patients with pre-existing mental disorders were more likely to be vaccinated against COVID-19 compared with the general population. The Sinopharm vaccine was most frequently applied. In the observed patients, 46.8% were infected, but just 7% had a medium or serious form of infection and were not vaccinated. Conclusions: In our study, the percentage of vaccinated psychiatric patients was greater than that in the general population, except in psychotic patients, who were mostly limited by fear. Such results can be explained by the high percentage of somatic comorbidities in this population and perhaps insufficient information about the positive effects of vaccination. Full article
(This article belongs to the Special Issue Personalized Medicine for COVID-19)
17 pages, 3687 KiB  
Article
Large-Scale Isolation of Milk Exosomes for Skincare
by Xue Wu, Jiuheng Shen, Youxiu Zhong, Xian Zhao, Wantong Zhou, Peifen Gao, Xudong Wang and Wenlin An
Pharmaceutics 2024, 16(7), 930; https://doi.org/10.3390/pharmaceutics16070930 - 11 Jul 2024
Cited by 7 | Viewed by 3868
Abstract
Exosomes are small membrane vesicles in a cell culture. They are secreted by most cells and originate from the endosomal pathway. A variety of proteins, lipids, and genetic materials have been shown to be carried by exosomes. Once taken up by neighboring or [...] Read more.
Exosomes are small membrane vesicles in a cell culture. They are secreted by most cells and originate from the endosomal pathway. A variety of proteins, lipids, and genetic materials have been shown to be carried by exosomes. Once taken up by neighboring or distant cells, the bioactive compounds in exosomes can regulate the condition of recipient cells. Typically, producing exosomes in large quantities requires cell culture, resulting in high production costs. However, exosomes are abundant in milk and can be isolated on a large scale at a low cost. In our study, we found that milk exosomes can promote the synthesis and reconstruction of stratum corneum lipids, enhance skin barrier function, and provide greater protection for the skin. Furthermore, milk exosomes have anti-inflammatory properties that can reduce skin irritation, redness, and other symptoms, giving immediate relief. They also exhibit antioxidant activity, which helps neutralize free radicals and slows down the skin aging process. Additionally, milk exosomes inhibit melanin production, aiding in skin whitening. Ongoing research has uncovered the benefits of milk exosomes for skin improvement and their application in cosmetics, skin healthcare, and other fields, and these applications are continuing to expand. Full article
(This article belongs to the Section Gene and Cell Therapy)
Show Figures

Figure 1

Back to TopTop